National and Kapodistrian University of Athens
Αποτελεσματικότητα των φυτο- serms στην αντιμετώπιση των αγγειοκινητικών διαταραχών, των ατροφικών καταστάσεων, των ψυχοδιανοητικών λειτουργιών και της υποστήριξης της οστικής πυκνότητας και ασφάλειά τους στο μαστό, το ενδομήτριο και το αγγειακό profile
Abstract
dc:descriptionINTRODUCTION. Menopause, a natural event in a woman’s life is characterized by loss ofreproductive function and decline in estrogen levels. Menopause is associated withmultiple symptoms such as hot flushes, night sweats, sleep disturbances, urinaryincontinence, decreased libido and sexual dysfunction, poor memory, anxiety anddepression that may affect the quality of life. Hot flushes have been documented tooccur in over 75% of midlife women and constitute the most characteristic anddistressing symptom of the climacteric. Moreover, menopause accelerates boneloss leading to osteoporosis. Postmenopausal osteoporosis and osteoporoticfractures comprise a serious threat to the aging population, presenting everincreasing incidence rates. The lifetime probability of hip fractures in women at theage of 50 exceeds 20% in developed countries, while the lifetime probability of anyosteoporotic fracture is over 40% in postmenopausal women.Hormonal therapy refers to the treatment of choice for the alleviation ofmenopausal symptoms; concerns, however, about its concomitant long-term healthrisks have limited its use.The Women’s Health Initiative (WHI) trial reported that the overall health risks oflong-term estrogen therapy - including increased risk of venothrombotic disease,breast cancer, stroke, and coronary artery disease - exceed its benefits. Alternativetreatment options are therefore sought for the alleviation of those climactericsymptoms lacking a stimulating effect on the breast or the clotting systemDT56a (Femarelle) is a unique enzymatic isolate of soybeans. In fact, itrepresents a composition of substances derived from soy through an enzymaticprocess resulting in a more potent extract with an efficacy of 8:1 compared to theraw material. Studies have also indicated that it acts as a phyto-SERM. DT56a hasbeen shown to increase bone mineral density in postmenopausal women and torelieve vasomotor symptoms with no effect on sex hormone levels or endometrialthickness.The purpose of our study was to evaluate the efficacy and safety of DT56a,compared to hormone replacement therapy (HRT), in symptomatic postmenopausal women. In fact, it was to evaluate the efficacy of DT56a,compared to HRT, in the management of menopausal symptoms, as well as itseffect on bone mineral density, lipid profile and endometrial thickness insymptomatic Greek postmenopausal women.METHODS89 postmenopausal or perimenopausal women attending the MenopauseClinic in 2 tertiary hospitals were studied in a prospective design. Women withclimacteric symptoms were randomly assigned to receive either DT56a (n=27) ororal low dose continuous combined HRT (n=26). Symptomatic women notwishing to receive any treatment served as controls (n=36). Menopausalsymptoms as assessed through the Kupperman index, serum total cholesterol,LDL-cholesterol, HDL-cholesterol, triglycerides, Apolipoprotein A1, ApolipoproteinB, calcium, as well as bone mineral density, endometrial thickness, andmammography were assessed at baseline and at 12 months.Criteria for inclusion in the study were the absence of menses for at least 12months, FSH >25mIU/ml, serum estradiol <50 pg/ml, endometrial thickness lessthan or equal to 5mm, the absence of gynecological malignancy, ischemic heartdisease, thromboembolism, diabetes mellitus, pharmacologically treateddyslipidemia, and non-treated thyroid dysfunction. Women who were past users ofHRT, tibolone or raloxifene were not included in the study unless they had beenoff-therapy for at least 6 months. All subjects gave informed consent and the studyprotocol received approval by the Ethics Committee of Attikon and AretaieionHospital.RESULTSPatients receiving HRT and DT56a showed a significant decrease in theintensity of menopausal symptoms (mean difference in Kupperman score, DT56agroup: -3.98, HRT group -5.601, no treatment group +1.76, p-value < 0.001). As faras Kupperman subscale scores are concerned, women in both treatment arms showed a significant reduction in hot flushes / night sweats (HRT baseline 2.25 ±1.24 final 0.25±0.56, p<0.001; DT56a baseline 2.17±0.94 final 0.75±0.69, p<0.001)and in sleep disturbances (HRT baseline 1.75 ± 0.93 final 0.34±0.47, p=0.01;DT56a baseline 1.96±1.08 final 0.91±0.82, p=0.02). None of the remainingsymptoms showed individually a significant difference in any of the two treatmentarms. The difference remained significant after adjusting for baseline values, yearssince menopause and baseline BMI.Lumbar spine bone mineral density T-score was significantly lower in womenreceiving no treatment, as opposed to the two treatment arms which showed nosignificant change (No treatment, baseline:-0.60, final: -0.85, p=0.001; HRT,baseline:-84, final -0.99, p=0.79; DT56a, baseline -0.51, final:-0.76, p=0.75). Nodifferences in femoral bone density, endometrial thickness or mammographyclassification were detected in any of the treatment arms. Likewise, in total, LDLand HDL cholesterol, triglycerides, Apolipoprotein A1 or Apolipoprotein B did notdiffer between the three groups. CONCLUSION. In conclusion, DT56a was effective in relieving menopausal symptoms ascompared to HRT in postmenopausal women. Women receiving DT56a or HRT didnot exhibit any change in bone mineral density, as compared to women notreceiving treatment who exhibited a decrease in lumbar spine BMD. No changeeither in endometrial thickness or mammography classification was recorded after12 months of treatment.DT56a may serve as an alternative to hormone replacement therapy for therelief of climacteric symptoms in postmenopausal women. DT56a might constitutean alternative treatment for symptomatic postmenopausal women who do not wishto receive or have contraindications to hormone replacement therapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Labos, Georgios
- Λάμπος, Γεώργιος
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41337